Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Human and pigeon suboptimal choice.

McDevitt MA, Diller JW, Pietrzykowski MO.

Learn Behav. 2019 Aug 19. doi: 10.3758/s13420-019-00391-8. [Epub ahead of print]

PMID:
31429009
2.

BRCA1 Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated miR-155 to Disrupt Myeloid Differentiation in Myeloid Malignancies.

Poh W, Dilley RL, Moliterno AR, Maciejewski JP, Pratz KW, McDevitt MA, Herman JG.

Clin Cancer Res. 2019 Apr 15;25(8):2513-2522. doi: 10.1158/1078-0432.CCR-18-0179. Epub 2019 Jan 28.

PMID:
30692098
3.

Frequency and value both matter in the suboptimal choice procedure.

Pisklak JM, McDevitt MA, Dunn RM, Spetch ML.

J Exp Anal Behav. 2019 Jan;111(1):1-11. doi: 10.1002/jeab.490. Epub 2018 Dec 19.

PMID:
30569554
4.

The influence of outcome delay on suboptimal choice.

McDevitt MA, Pisklak JM, Spetch M, Dunn R.

Behav Processes. 2018 Dec;157:279-285. doi: 10.1016/j.beproc.2018.10.008. Epub 2018 Oct 28.

PMID:
30394293
5.

Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.

Norsworthy KJ, DeZern AE, Tsai HL, Hand WA, Varadhan R, Gore SD, Gojo I, Pratz K, Carraway HE, Showel M, McDevitt MA, Gladstone D, Ghiaur G, Prince G, Seung AH, Benani D, Levis MJ, Karp JE, Smith BD.

Leuk Res. 2017 Oct;61:25-32. doi: 10.1016/j.leukres.2017.08.009. Epub 2017 Aug 30. Review.

6.

Recurrent genetic defects on chromosome 5q in myeloid neoplasms.

Hosono N, Makishima H, Mahfouz R, Przychodzen B, Yoshida K, Jerez A, LaFramboise T, Polprasert C, Clemente MJ, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Cui E, Verma AK, McDevitt MA, List AF, Saunthararajah Y, Sekeres MA, Boultwood J, Ogawa S, Maciejewski JP.

Oncotarget. 2017 Jan 24;8(4):6483-6495. doi: 10.18632/oncotarget.14130.

7.

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.

Pratz KW, Rudek MA, Gojo I, Litzow MR, McDevitt MA, Ji J, Karnitz LM, Herman JG, Kinders RJ, Smith BD, Gore SD, Carraway HE, Showel MM, Gladstone DE, Levis MJ, Tsai HL, Rosner G, Chen A, Kaufmann SH, Karp JE.

Clin Cancer Res. 2017 Feb 15;23(4):899-907. doi: 10.1158/1078-0432.CCR-16-1274. Epub 2016 Aug 22.

8.

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE.

Clin Cancer Res. 2017 Feb 1;23(3):697-706. doi: 10.1158/1078-0432.CCR-16-0984. Epub 2016 Aug 8.

9.

Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.

Pratz KW, Koh BD, Patel AG, Flatten KS, Poh W, Herman JG, Dilley R, Harrell MI, Smith BD, Karp JE, Swisher EM, McDevitt MA, Kaufmann SH.

Clin Cancer Res. 2016 Aug 1;22(15):3894-902. doi: 10.1158/1078-0432.CCR-15-2351. Epub 2016 Mar 15.

10.

When good news leads to bad choices.

McDevitt MA, Dunn RM, Spetch ML, Ludvig EA.

J Exp Anal Behav. 2016 Jan;105(1):23-40. doi: 10.1002/jeab.192. Review.

PMID:
26781050
11.

When good pigeons make bad decisions: Choice with probabilistic delays and outcomes.

Pisklak JM, McDevitt MA, Dunn RM, Spetch ML.

J Exp Anal Behav. 2015 Nov;104(3):241-51. doi: 10.1002/jeab.177.

PMID:
26676182
12.

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, Spitzer G, Odenike O, McDevitt MA, Röth A, Daskalakis M, Burington B, Stuart M, Snyder DS.

N Engl J Med. 2015 Sep 3;373(10):920-8. doi: 10.1056/NEJMoa1503479.

13.

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.

Kasamon YL, Bolaños-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA, Rosner GL, Brodsky RA, Perica K, Smith BD, Gladstone DE, Swinnen LJ, Showel MM, Matsui WH, Huff CA, Borrello I, Pratz KW, McDevitt MA, Gojo I, Dezern AE, Shanbhag S, Levis MJ, Luznik L, Ambinder RF, Fuchs EJ, Jones RJ.

J Clin Oncol. 2015 Oct 1;33(28):3152-61. doi: 10.1200/JCO.2014.60.4777. Epub 2015 Aug 10.

14.

Erratum for Elagib et al., Jun Blockade of Erythropoiesis: Role for Repression of GATA-1 by HERP2.

Elagib KE, Xiao M, Hussaini IM, Delehanty LL, Palmer LA, Racke FK, Birrer MJ, Ganapathy-Kanniappan S, McDevitt MA, Goldfarb AN.

Mol Cell Biol. 2015 Jun;35(12):2215. doi: 10.1128/MCB.00374-15. No abstract available.

15.

A critical role for the host mediator macrophage migration inhibitory factor in the pathogenesis of malarial anemia.

McDevitt MA, Xie J, Ganapathy-Kanniappan S, Griffith J, Liu A, McDonald C, Thuma P, Gordeuk VR, Metz CN, Mitchell R, Keefer J, David J, Leng L, Bucala R.

J Exp Med. 2015 May 4;212(5):825. doi: 10.1084/jem.2005239804172015c. No abstract available.

16.

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner GL, Kanakry CG, Perica K, Symons HJ, Brodsky RA, Gladstone DE, Huff CA, Pratz KW, Prince GT, Dezern AE, Gojo I, Matsui WH, Borrello I, McDevitt MA, Swinnen LJ, Smith BD, Levis MJ, Ambinder RF, Luznik L, Jones RJ, Fuchs EJ, Kasamon YL.

Blood. 2015 May 7;125(19):3024-31. doi: 10.1182/blood-2015-01-623991. Epub 2015 Mar 26.

17.

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.

Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Powell JD, Pratz KW, DeZern AE, Showel MM, McDevitt MA, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Blood. 2014 Dec 11;124(25):3817-27. doi: 10.1182/blood-2014-07-587477. Epub 2014 Oct 14.

18.

Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.

Dilley RL, Poh W, Gladstone DE, Herman JG, Showel MM, Karp JE, McDevitt MA, Pratz KW.

Leuk Res. 2014 Mar;38(3):411-7. doi: 10.1016/j.leukres.2013.12.019. Epub 2013 Dec 30.

19.

Recurrent genetic defects on chromosome 7q in myeloid neoplasms.

Hosono N, Makishima H, Jerez A, Yoshida K, Przychodzen B, McMahon S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Gómez-Seguí I, Verma AK, McDevitt MA, Sekeres MA, Ogawa S, Maciejewski JP.

Leukemia. 2014 Jun;28(6):1348-51. doi: 10.1038/leu.2014.25. Epub 2014 Jan 16. No abstract available.

PMID:
24429498
20.

A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.

Zeidner JF, Karp JE, Blackford AL, Smith BD, Gojo I, Gore SD, Levis MJ, Carraway HE, Greer JM, Ivy SP, Pratz KW, McDevitt MA.

Haematologica. 2014 Apr;99(4):672-8. doi: 10.3324/haematol.2013.097246. Epub 2013 Dec 20.

21.

Effects of changeover delay on response allocation during probe tests.

McDevitt MA, Bell MC.

J Exp Anal Behav. 2013 Sep;100(2):135-46. doi: 10.1002/jeab.44. Epub 2013 Aug 23.

PMID:
24019008
22.

Somatic SETBP1 mutations in myeloid malignancies.

Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y, Ng KP, Gudmundsson KO, Vishwakarma BA, Jerez A, Gomez-Segui I, Takahashi M, Shiraishi Y, Nagata Y, Guinta K, Mori H, Sekeres MA, Chiba K, Tanaka H, Muramatsu H, Sakaguchi H, Paquette RL, McDevitt MA, Kojima S, Saunthararajah Y, Miyano S, Shih LY, Du Y, Ogawa S, Maciejewski JP.

Nat Genet. 2013 Aug;45(8):942-6. doi: 10.1038/ng.2696. Epub 2013 Jul 7.

23.

Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies.

Gómez-Seguí I, Makishima H, Jerez A, Yoshida K, Przychodzen B, Miyano S, Shiraishi Y, Husseinzadeh HD, Guinta K, Clemente M, Hosono N, McDevitt MA, Moliterno AR, Sekeres MA, Ogawa S, Maciejewski JP.

Leukemia. 2013 Sep;27(9):1943-6. doi: 10.1038/leu.2013.179. Epub 2013 Jun 14. No abstract available.

PMID:
23765226
24.

Granulocyte colony-stimulating factor receptor T595I (T618I) mutation confers ligand independence and enhanced signaling.

Mehta HM, Glaubach T, Long A, Lu H, Przychodzen B, Makishima H, McDevitt MA, Cross NC, Maciejewski J, Corey SJ.

Leukemia. 2013 Dec;27(12):2407-10. doi: 10.1038/leu.2013.164. Epub 2013 Jun 6. No abstract available.

PMID:
23739288
25.

Burst-forming unit-erythroid assays to distinguish cellular bone marrow failure disorders.

DeZern AE, Pu J, McDevitt MA, Jones RJ, Brodsky RA.

Exp Hematol. 2013 Sep;41(9):808-16. doi: 10.1016/j.exphem.2013.04.013. Epub 2013 May 6.

26.

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.

Khan SN, Jankowska AM, Mahfouz R, Dunbar AJ, Sugimoto Y, Hosono N, Hu Z, Cheriyath V, Vatolin S, Przychodzen B, Reu FJ, Saunthararajah Y, O'Keefe C, Sekeres MA, List AF, Moliterno AR, McDevitt MA, Maciejewski JP, Makishima H.

Leukemia. 2013 Jun;27(6):1301-9. doi: 10.1038/leu.2013.80. Epub 2013 Mar 14.

PMID:
23486531
27.

Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.

Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten KS, Peterson K, Schneider P, Mackey K, Freshwater T, Levis MJ, McDevitt MA, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Isaacs R, Kaufmann SH.

Clin Cancer Res. 2012 Dec 15;18(24):6723-31. doi: 10.1158/1078-0432.CCR-12-2442. Epub 2012 Oct 23.

28.

Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia.

Kar SA, Jankowska A, Makishima H, Visconte V, Jerez A, Sugimoto Y, Muramatsu H, Traina F, Afable M, Guinta K, Tiu RV, Przychodzen B, Sakaguchi H, Kojima S, Sekeres MA, List AF, McDevitt MA, Maciejewski JP.

Haematologica. 2013 Jan;98(1):107-13. doi: 10.3324/haematol.2012.064048. Epub 2012 Jul 6.

29.

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Karp JE, Garrett-Mayer E, Estey EH, Rudek MA, Smith BD, Greer JM, Drye DM, Mackey K, Dorcy KS, Gore SD, Levis MJ, McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, Showel MM, Othus M, Doyle LA, Wright JJ, Pagel JM.

Haematologica. 2012 Nov;97(11):1736-42. doi: 10.3324/haematol.2012.062539. Epub 2012 Jun 24.

30.

Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.

Zeidan AM, Ricklis RM, Carraway HE, Yun HD, Greer JM, Smith BD, Levis MJ, McDevitt MA, Pratz KW, Showel MM, Gladstone DE, Gore SD, Karp JE.

Br J Haematol. 2012 Jul;158(2):198-207. doi: 10.1111/j.1365-2141.2012.09142.x. Epub 2012 May 18.

31.

Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.

Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boultwood J, Mufti GJ, Maciejewski JP.

Blood. 2012 Jun 21;119(25):6109-17. doi: 10.1182/blood-2011-12-397620. Epub 2012 May 2.

32.

Erythroid-specific transcriptional changes in PBMCs from pulmonary hypertension patients.

Cheadle C, Berger AE, Mathai SC, Grigoryev DN, Watkins TN, Sugawara Y, Barkataki S, Fan J, Boorgula M, Hummers L, Zaiman AL, Girgis R, McDevitt MA, Johns RA, Wigley F, Barnes KC, Hassoun PM.

PLoS One. 2012;7(4):e34951. doi: 10.1371/journal.pone.0034951. Epub 2012 Apr 24.

33.

Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.

Jerez A, Gondek LP, Jankowska AM, Makishima H, Przychodzen B, Tiu RV, O'Keefe CL, Mohamedali AM, Batista D, Sekeres MA, McDevitt MA, Mufti GJ, Maciejewski JP.

J Clin Oncol. 2012 Apr 20;30(12):1343-9. doi: 10.1200/JCO.2011.36.1824. Epub 2012 Feb 27.

34.

The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells.

Pu JJ, Hu R, Mukhina GL, Carraway HE, McDevitt MA, Brodsky RA.

Haematologica. 2012 Aug;97(8):1225-33. doi: 10.3324/haematol.2011.048215. Epub 2012 Feb 7.

35.

Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies.

McDevitt MA.

Semin Oncol. 2012 Feb;39(1):109-22. doi: 10.1053/j.seminoncol.2011.11.003. Review.

PMID:
22289497
36.

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.

Karp JE, Vener TI, Raponi M, Ritchie EK, Smith BD, Gore SD, Morris LE, Feldman EJ, Greer JM, Malek S, Carraway HE, Ironside V, Galkin S, Levis MJ, McDevitt MA, Roboz GR, Gocke CD, Derecho C, Palma J, Wang Y, Kaufmann SH, Wright JJ, Garret-Mayer E.

Blood. 2012 Jan 5;119(1):55-63. doi: 10.1182/blood-2011-08-370825. Epub 2011 Oct 14.

37.

Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O'Keefe C, Hsi ED, List A, Sekeres MA, Rao A, McDevitt MA, Maciejewski JP.

Blood. 2011 Oct 6;118(14):3932-41. doi: 10.1182/blood-2010-10-311019. Epub 2011 Aug 9.

38.

Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.

Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR.

Haematologica. 2011 Oct;96(10):1462-9. doi: 10.3324/haematol.2011.045591. Epub 2011 Jun 28.

39.

Large-vessel vasculitis as an early manifestation of chronic myelomonocytic leukemia.

Park JK, Gelber AC, Zheng G, McDevitt MA, Gocke CD, Baer AN.

J Clin Oncol. 2011 Jul 10;29(20):e601-3. doi: 10.1200/JCO.2011.34.6965. Epub 2011 Apr 25. No abstract available.

PMID:
21519013
40.

CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.

Makishima H, Jankowska AM, McDevitt MA, O'Keefe C, Dujardin S, Cazzolli H, Przychodzen B, Prince C, Nicoll J, Siddaiah H, Shaik M, Szpurka H, Hsi E, Advani A, Paquette R, Maciejewski JP.

Blood. 2011 May 26;117(21):e198-206. doi: 10.1182/blood-2010-06-292433. Epub 2011 Feb 23.

41.

Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies.

Tiu RV, Gondek LP, O'Keefe CL, Elson P, Huh J, Mohamedali A, Kulasekararaj A, Advani AS, Paquette R, List AF, Sekeres MA, McDevitt MA, Mufti GJ, Maciejewski JP.

Blood. 2011 Apr 28;117(17):4552-60. doi: 10.1182/blood-2010-07-295857. Epub 2011 Feb 1.

42.

KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation.

Lee YN, Brandal S, Noel P, Wentzel E, Mendell JT, McDevitt MA, Kapur R, Carter M, Metcalfe DD, Takemoto CM.

Blood. 2011 Mar 31;117(13):3629-40. doi: 10.1182/blood-2010-07-293548. Epub 2011 Jan 27.

43.

Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.

Karp JE, Smith BD, Resar LS, Greer JM, Blackford A, Zhao M, Moton-Nelson D, Alino K, Levis MJ, Gore SD, Joseph B, Carraway H, McDevitt MA, Bagain L, Mackey K, Briel J, Doyle LA, Wright JJ, Rudek MA.

Blood. 2011 Mar 24;117(12):3302-10. doi: 10.1182/blood-2010-09-310862. Epub 2011 Jan 14.

44.

5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.

Bolaños-Meade J, Smith BD, Gore SD, McDevitt MA, Luznik L, Fuchs EJ, Jones RJ.

Biol Blood Marrow Transplant. 2011 May;17(5):754-8. doi: 10.1016/j.bbmt.2010.10.008. Epub 2010 Oct 15.

45.

Dual effects on choice of conditioned reinforcement frequency and conditioned reinforcement value.

McDevitt MA, Williams BA.

J Exp Anal Behav. 2010 Mar;93(2):147-55. doi: 10.1901/jeab.2010.93-147.

46.

Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation.

Griffiths EA, Gore SD, Hooker C, McDevitt MA, Karp JE, Smith BD, Mohammad HP, Ye Y, Herman JG, Carraway HE.

Leuk Lymphoma. 2010 Sep;51(9):1711-9. doi: 10.3109/10428194.2010.496505.

47.

Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.

Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z, Saunthararajah Y, Guinta K, Keddache MA, Putnam P, Sekeres MA, Moliterno AR, List AF, McDevitt MA, Maciejewski JP.

Leukemia. 2010 Oct;24(10):1799-804. doi: 10.1038/leu.2010.167. Epub 2010 Aug 19. No abstract available.

PMID:
20724984
48.

Lenalidomide-induced acute interstitial nephritis.

Lipson EJ, Huff CA, Holanda DG, McDevitt MA, Fine DM.

Oncologist. 2010;15(9):961-4. doi: 10.1634/theoncologist.2010-0070. Epub 2010 Aug 13. No abstract available.

49.

Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia.

Griffiths EA, Gore SD, Hooker CM, Mohammad HP, McDevitt MA, Smith BD, Karp JE, Herman JG, Carraway HE.

Epigenetics. 2010 Oct 1;5(7):590-600. Epub 2010 Oct 1.

50.

The Erg-onomics of myeloproliferation in Down syndrome.

McDevitt MA.

Blood. 2010 May 13;115(19):3859-60. doi: 10.1182/blood-2010-02-263640. No abstract available.

Supplemental Content

Loading ...
Support Center